1. Key Insights
2. Executive Summary
3. SWOT Analysis
4. wAIHA Market Overview at a Glance
4.1. Market Share (%) Distribution of wAIHA in 2017
4.2. Market Share (%) Distribution of wAIHA in 2030
5. Disease Background and Overview
5.1. Introduction
5.2. Types
5.3. Causes
5.4. Signs and Symptoms
5.5. Pathophysiology
5.6. Manifestations
5.7. Diagnosis
Immunohematological assessment of patients with AIHA
DAT-negative AIHA
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. KOL Views
6.3. 7MM Total Prevalent Patient Population of wAIHA
6.4. Assumptions and Rationale: 7MM
7. Country Wise-Epidemiology of wAIHA
7.1. The United States
7.1.1. Total Prevalent Cases of AIHA in the United States
7.1.2. Diagnosed Prevalence of wAIHA in the United States
7.1.3. Type-specific Prevalence of wAIHA in the United States
7.1.4. Gender-specific Prevalence of wAIHA in the United States
7.2. EU5
7.2.1. Germany
7.2.1.1. Total Prevalent Cases of AIHA in Germany
7.2.1.2. Diagnosed Prevalence of wAIHA in Germany
7.2.1.3. Type-specific Prevalence of wAIHA in Germany
7.2.1.4. Gender-specific Prevalence of wAIHA in Germany
7.2.2. France
7.2.2.1. Total Prevalent Cases of AIHA in France
7.2.2.2. Diagnosed Prevalence of wAIHA in France
7.2.2.3. Type-specific Prevalence of wAIHA in France
7.2.2.4. Gender-specific Prevalence of wAIHA in France
7.2.3. Italy
7.2.3.1. Total Prevalent Cases of AIHA in Italy
7.2.3.2. Diagnosed Prevalence of wAIHA in Italy
7.2.3.3. Type-specific Prevalence of wAIHA in Italy
7.2.3.4. Gender-specific Prevalence of wAIHA in Italy
7.2.4. Spain
7.2.4.1. Total Prevalent Cases of AIHA in Spain
7.2.4.2. Diagnosed Prevalence of wAIHA in Spain
7.2.4.3. Type-specific Prevalence of wAIHA in Spain
7.2.4.4. Gender-specific Prevalence of wAIHA in Spain
7.2.5. The United Kingdom
7.2.5.1. Total Prevalent Cases of AIHA in the UK
7.2.5.2. Diagnosed Prevalence of wAIHA in the UK
7.2.5.3. Type-specific Prevalence of wAIHA in the UK
7.2.5.4. Gender-specific Prevalence of wAIHA in the UK
7.3. Japan
7.3.1. Total Prevalent Cases of AIHA in Japan
7.3.2. Diagnosed Prevalence of wAIHA in Japan
7.3.3. Type-specific Prevalence of wAIHA in Japan
7.3.4. Gender-specific Prevalence of wAIHA in Japan
8. Treatment and Management of wAIHA
8.1. Sequential approach to treatment options for w-AIHA and common dosing regimens
8.1.1. First-line therapy
8.1.1.1. Corticosteroids
8.1.2. Second-line therapy
8.1.2.1. Splenectomy
8.1.2.2. Rituximab
8.1.2.3. Immunosuppressive drugs
8.1.2.4. Other Options
8.2. British Guidelines for WAIHA treatment
9. Case Study
10. Patient Journey
12. Unmet Needs
13. Emerging Therapies
13.1. Fostamatinib: Rigel Pharmaceuticals
13.1.1. Product Description
13.1.2. Other Development Activities
13.1.3. Clinical Development
13.1.3.1. Clinical Trials Information
13.1.4. Safety and Efficacy
13.2. APL-2: Apellis Pharmaceuticals, Inc.
13.2.1. Product Description
13.2.2. Other Development Activities
13.2.3. Clinical Development
13.2.3.1. Clinical Trials Information
13.2.4. Safety and Efficacy
13.3. M281: Momenta Pharmaceuticals
13.3.1. Product Description
13.3.2. Other Development Activities
13.3.3. Clinical Development
13.3.3.1. Clinical Trials Information
13.3.4. Safety and Efficacy
13.4. IMVT-1401: Immunovant
13.4.1. Product Description
13.4.2. Other Development Activities
13.4.3. Clinical Development
13.4.3.1. Clinical Trials Information
13.4.4. Safety and Efficacy
13.5. ALXN1830/SYNT001: Alexion Pharmaceuticals, Inc.
13.5.1. Product Description
13.5.2. Other Development Activities
13.5.3. Clinical Development
13.5.4. Clinical Trials Information
13.5.5. Product Profile
14. Other Promising Candidates
14.1. BIV009 (Sutimlimab): Sanofi
14.1.1. Product Description
14.1.2. Other Development Activities
14.1.3. Clinical Development
14.1.4. Clinical Trials Information
14.1.5. Safety and Efficacy
14.1.6. Product Profile
15. wAIHA: 7 Major Market Analysis
15.1. Key Findings
15.2. Market Size of wAIHA in 7MM
15.3. KOL Views
16. Market Outlook by Country
16.1. The United States: Market Outlook
16.2. United States Market Size
16.2.1. Total Market Size of wAIHA
16.2.2. Market Size of wAIHA by Therapies
17. EU-5 Countries: Market Outlook
17.1. Germany
17.1.1. Total Market size of wAIHA
17.1.2. Market Size of wAIHA by Therapies
17.2. France
17.2.1. Total Market Size of wAIHA
17.2.2. Market Size of wAIHA by Therapies
17.3. Italy
17.3.1. Total Market Size of wAIHA
17.3.2. Market Size of wAIHA by Emerging Therapies
17.4. Spain
17.4.1. Total Market Size of wAIHA
17.4.2. Market Size of wAIHA by Therapies
17.5. United Kingdom
17.5.1. Total Market Size of wAIHA
17.5.2. Market Size of wAIHA by Therapies
18. Japan: Market Outlook
18.1.1. Total Market Size of wAIHA
18.1.2. Market Size of wAIHA by Therapies
19. Market Drivers
20. Market Barriers
21. Appendix
21.1. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
Table 1: Classification of wAIHATable 2: Prevalent Patient Population of wAIHA in 7MM (2017-2030)
Table 3: Total Prevalent Cases of AIHA in the United States (2017-2030)
Table 4: Diagnosed Prevalence of wAIHA in the United States (2017-2030)
Table 5: Type-specific Prevalence of wAIHA in the United States (2017-2030)
Table 6: Gender-specific Prevalence of wAIHA in the United States (2017-2030)
Table 7: Total Prevalent Cases of AIHA in Germany (2017-2030)
Table 8: Diagnosed Prevalence of wAIHA in Germany (2017-2030)
Table 9: Type-specific Prevalence of wAIHA in Germany (2017-2030)
Table 10: Gender-specific Prevalence of wAIHA in Germany (2017-2030)
Table 11: Total Prevalent Cases of AIHA in France (2017-2030)
Table 12: Diagnosed Prevalence of wAIHA in France (2017-2030)
Table 13: Type-specific Prevalence of wAIHA in France (2017-2030)
Table 14: Gender-specific Prevalence of wAIHA in France (2017-2030)
Table 15: Total Prevalent Cases of AIHA in Italy (2017-2030)
Table 16: Diagnosed Prevalence of wAIHA in Italy (2017-2030)
Table 17: Type-specific Prevalence of wAIHA in Italy (2017-2030)
Table 18: Gender-specific Prevalence of wAIHA in Italy (2017-2030)
Table 19: Total Prevalent Cases of AIHA in Spain (2017-2030)
Table 20: Diagnosed Prevalence of wAIHA in Spain (2017-2030)
Table 21: Type-specific Prevalence of wAIHA in Spain (2017-2030)
Table 22: Gender-specific Prevalence of wAIHA in Spain (2017-2030)
Table 23: Total Prevalent Cases of AIHA in the United Kingdom (2017-2030)
Table 24: Diagnosed Prevalence of wAIHA in the United Kingdom (2017-2030)
Table 25: Type-specific Prevalence of wAIHA in the United Kingdom (2017-2030)
Table 26: Gender-specific Prevalence of wAIHA in the United Kingdom (2017-2030)
Table 27: Total Prevalent Cases of AIHA in Japan (2017-2030)
Table 28: Diagnosed Prevalence of wAIHA in Japan (2017-2030)
Table 29: Type-specific Prevalence of wAIHA in Japan (2017-2030)
Table 30: Gender-specific Prevalence of wAIHA in Japan (2017-2030)
Table 31: Treatment Flow
Table 32: Fostamatinib, Clinical Trial Description, 2020
Table 33: APL-2, Clinical Trial Description, 2020
Table 34: M281, Clinical Trial Description, 2019
Table 35: RVT-1401, Clinical Trial Description, 2020
Table 36: SYNT001, Clinical Trial Description, 2020
Table 37: BIV009, Clinical Trial Description, 2020
Table 38: 7 Major Market Size of wAIHA in USD Million (2017-2030)
Table 39: United States Market Size of wAIHA in USD Million (2017-2030)
Table 40: The US Market Size of wAIHA by Therapies in USD Million (2017-2030)
Table 41: Germany Market Size of wAIHA in USD Million (2017-2030)
Table 42: Germany Market Size of wAIHA by Therapies in USD Million (2017-2030)
Table 43: France Market Size of wAIHA in USD Million (2017-2030)
Table 44: France Market Size of wAIHA by Therapies in USD Million (2017-2030)
Table 45: Italy Market Size of wAIHA in USD Million (2017-2030)
Table 46: Italy Market Size of wAIHA by Therapies in USD Million (2017-2030)
Table 47: Spain Market Size of wAIHA in USD Million (2017-2030)
Table 48: Spain Market Size of wAIHA by Therapies in USD Million (2017-2030)
Table 49: United Kingdom Market Size of wAIHA in USD Million (2017-2030)
Table 50: UK Market Size of wAIHA by Therapies in USD Million (2017-2030)
Table 51: Japan Market Size of wAIHA in USD Million (2017-2030)
Table 52: Japan Market Size of wAIHA by Therapies in USD Million (2017-2030)
List of figures
Figure 1: SWOT Analysis of wAIHa
Figure 2 : Mechanisms of hemolysis in warm antibody autoimmune hemoytic anemia
Figure 3: Clinical-serologic associations with the direct Coombs test
Figure 4: Prevalent Patient Population of wAIHA in 7MM (2017-2030)
Figure 5: Total Prevalent Cases of AIHA in the United States (2017-2030)
Figure 6: Diagnosed Prevalence of wAIHA in the United States (2017-2030)
Figure 7: Type-specific Prevalence of wAIHA in the United States (2017-2030)
Figure 8: Gender-specific Prevalence of wAIHA in the United States (2017-2030)
Figure 9: Total Prevalent Cases of AIHA in Germany (2017-2030)
Figure 10: Diagnosed Prevalence of wAIHA in Germany (2017-2030)
Figure 11: Type-specific Prevalence of wAIHA in Germany (2017-2030)
Figure 12: Gender-specific Prevalence of wAIHA in Germany (2017-2030)
Figure 13: Total Prevalent Cases of AIHA in France (2017-2030)
Figure 14:Diagnosed Prevalence of wAIHA in France (2017-2030)
Figure 15: Type-specific Prevalence of wAIHA in France (2017-2030)
Figure 16: Gender-specific Prevalence of wAIHA in France (2017-2030)
Figure 17: Total Prevalent Cases of AIHA in Italy (2017-2030)
Figure 18: Diagnosed Prevalence of wAIHA in Italy (2017-2030)
Figure 19: Type-specific Prevalence of wAIHA in Italy (2017-2030)
Figure 20: Gender-specific Prevalence of wAIHA in Italy (2017-2030)
Figure 21: Total Prevalent Cases of AIHA in Spain (2017-2030)
Figure 22: Diagnosed Prevalence of wAIHA in Spain (2017-2030)
Figure 23: Type-specific Prevalence of wAIHA in Spain (2017-2030)
Figure 24: Gender-specific Prevalence of wAIHA in Spain (2017-2030)
Figure 25: Total Prevalent Cases of AIHA in the UK (2017-2030)
Figure 26: Diagnosed Prevalence of wAIHA in the UK (2017-2030)
Figure 27: Type-specific Prevalence of wAIHA in the UK (2017-2030)
Figure 28: Gender-specific Prevalence of wAIHA in the UK (2017-2030)
Figure 29: Total Prevalent Cases of AIHA in Japan (2017-2030)
Figure 30: Diagnosed Prevalence of wAIHA in Japan (2017-2030)
Figure 31: Type-specific Prevalence of wAIHA in Japan (2017-2030)
Figure 32: Gender-specific Prevalence of wAIHA in Japan (2017-2030)
Figure 33: Treatment algorithm for warm AIHA in adults
Figure 34: Mechanisms of hemolysis in warm antibody autoimmune hemolytic anemia
Figure 35: Unmet Needs of wAIHA
Figure 36: 7 Major Market Size of wAIHA in USD Million (2017-2030)
Figure 37: Market Size of wAIHA in the United States, USD Million (2017-2030)
Figure 38: The US Market Size of wAIHA by Therapies in USD Million (2017-2030)
Figure 39: Market Size of wAIHA in Germany, USD Million (2017-2030)
Figure 40: The US Market Size of wAIHA by Therapies in USD Million (2017-2030)
Figure 41: Market Size of wAIHA in France USD Million (2017-2030)
Figure 42: The US Market Size of wAIHA by Emerging Therapies in USD Million (2017-2030)
Figure 43: Market Size of wAIHA in Italy, USD Million (2017-2030)
Figure 44: Italy Market Size of wAIHA by Therapies in USD Million (2017-2030)
Figure 45: Market Size of wAIHA in Spain, USD Million (2017-2030)
Figure 46: Spain Market Size of wAIHA by Therapies in USD Million (2017-2030)
Figure 47: Market Size of wAIHA in the United Kingdom, USD Million (2017-2030)
Figure 48: UK Market Size of wAIHA by Therapies in USD Million (2017-2030)
Figure 49: Market Size of wAIHA in Japan, USD Million (2017-2030)
Figure 50: Japan Market Size of wAIHA by Therapies in USD Million (2017-2030)
Figure 51: Market Drivers
Figure 52: Market Barriers
【免責事項】
https://www.marketreport.jp/reports-disclaimer